RBI’s New Rules on Bank Mis-Selling: What Investors Must Know
Your bank’s relationship manager was never your financial advisor. They had monthly product targets, commission incentives, and no legal obligation to act in your interest. On June 15, 2026, the RBI formally changed that for the first time, defining mis-selling as a regulatory offence and making banks financially liable for it. The new circular, effective January 1, 2027, mandates written suitability assessments before every product sale, makes explicit consent the default, bans insurance bundling with loans, and requires full refunds where mis-selling is proven. If your bank ever pitched a ULIP as a “better FD,” this blog explains exactly what your rights now are and what to do about it.
Introduction
Your bank’s relationship manager was never your financial advisor. They were the bank’s distribution channel with a monthly product target, an incentive tied to what they sold, and no legal obligation to act in your interest. On June 15, 2026, the RBI’s new rules on bank mis-selling of investment products formally named this practice, defined it as a regulatory offence, and made banks financially liable for it for the first time.
The Problem RBI’s New Mis-Selling Rules Are Directly Addressing
For years, India’s banking channel has led every other distribution channel in mis-selling complaints. According to IRDAI’s FY25 annual report, mis-selling grievances against life insurers rose 14.3% year-on-year to 26,667 in FY25, and IRDAI’s own member publicly called the level “alarming” at the CII Financial Summit in September 2024. Banks and broker channels consistently ranked highest among distribution sources in these complaints.
The pattern behind these numbers was consistent. Bank RMs presented ULIPs as “special FDs” to customers visiting branches for deposit renewals. They showed historical fund performance as projected future returns, a practice IRDAI explicitly prohibits. They bundled insurance products with home loan approvals without telling borrowers they had any choice. And they did this because their performance reviews rewarded product volume, not client outcomes.
IRDAI flagged the problem repeatedly. The RBI warned banks repeatedly. What neither regulator had, until now, was a formal definition of the offence and a mandatory financial consequence attached to it.
What RBI’s 2026 Circular on Bank Mis-Selling Actually Changes
RBI’s Responsible Business Conduct Second Amendment Directions, dated June 15, 2026 come into effect January 1, 2027 and apply to all commercial banks except small finance banks, payments banks, regional rural banks, and local area banks.
The circular makes five changes that directly affect investors.
1. It defines mis-selling for the first time. Under paragraph 4(20A), mis-selling now formally includes: selling a product unsuitable for your profile even if you signed; selling without complete or accurate information; selling without explicit consent; and bundling a product with a loan as a condition of approval. Each is a named regulatory offence.
2. It mandates suitability assessment before every investment product sale. Under paragraph 85P, banks must assess your age, income, risk tolerance, financial literacy, and investment horizon before selling you any investment product. If your bank skipped this, and most did, the sale now sits on structurally weaker ground.
3. It makes explicit consent mandatory and sets the default to “No.” Under paragraph 85I, the default option on every consent screen must be “No / I do not agree.” Pre-ticked boxes and blanket OTP approvals for multiple products no longer satisfy the consent requirement.
4. It prohibits compulsory bundling. Under paragraph 85V, banks cannot make a loan conditional on purchasing their insurance or investment product. Where insurance is genuinely required as a loan risk mitigant, you must receive the option to purchase it from any provider, not only the bank’s distribution partner.
5. It mandates full refunds where mis-selling is established. Under paragraph 85Z, banks must refund the entire amount you paid for a mis-sold product and compensate you for losses arising from the sale.
How Banks Mis-Sold Through Their Own Apps
The circular’s Annex IIA defines eleven dark patterns banks must now remove from their digital interfaces. These include false urgency (countdown timers on loan offers), basket sneaking (auto-adding insurance during loan applications without disclosure), confirm shaming (“No, I don’t want to protect my account”), bait and switch (advertising a lower rate and applying a higher one), and drip pricing (concealing processing fees until after you commit).
Banks and their digital sales agents must now conduct periodic internal audits to identify and remove these features. If a banking app pop-up has ever redirected you to a personal loan page when you clicked close, that specific practice is now a named regulatory violation.
Practical Scenario:
A 58-year-old retired government officer walks into his bank branch in 2022 to renew an FD. His RM tells him the bank has a “better product” with the same capital safety, higher returns, and tax benefits under Section 80C. He signs. What he signs is a ULIP application form.
This is not a hypothetical. Outlook Money’s April 2025 cover story documented exactly this pattern: senior citizens asking for FDs being handed ULIP forms by RMs, with the product described as a “similar product from their sister concern where they will get double the returns.” The same investigation quoted an RM at a private bank in Kolkata admitting on record: “People come to our bank to invest in FD products, and we try to sell them insurance plans. It also helps me fulfil my targets.”
The retired officer’s ULIP carried a five-year lock-in. He received no written suitability assessment. He was told it was a single-premium plan. It was not. When the second-year premium demand arrived, he could not pay it and surrendering the policy early meant absorbing a direct loss on capital he could not afford to lose.
Under the RBI’s circular, this transaction fails on three counts: no suitability assessment against his age and risk profile, no explicit consent for a multi-premium structure, and a product demonstrably unsuitable for a retired investor seeking capital preservation.
Conclusion
For products sold after January 1, 2027, file a written complaint with your bank within 30 days of receiving your signed agreement, citing paragraph 85Z. For older products, approach IRDAI’s Bima Bharosa portal for insurance complaints or the RBI Banking Ombudsman for banking conduct grievances.
The more important question is not whether you can file a complaint. It is what your portfolio actually looks like after years of advice from someone whose income depended on what you bought. Most investors carrying these products have never had someone to review their portfolio without a product to sell on the other side.
That is what a portfolio review is for. To tell you what is actually there, what it is costing you, and what belongs versus what was sold to you. At Moneyvesta, we are SEBI-registered and fee-only; our only income is what you pay us directly, which means our only job is to be honest with you.